These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Maxillary sinus floor augmentation and dental implant placement using dentin matrix protein-1 gene-modified bone marrow stromal cells mixed with deproteinized boving bone: A comparative study in beagles.
    Author: Liu X, Li Q, Wang F, Wang Z.
    Journal: Arch Oral Biol; 2016 Apr; 64():102-8. PubMed ID: 26826470.
    Abstract:
    OBJECTIVE: The aim of the study was to evaluate the effects of the combined use of dentin matrix protein-1 (DMP1) gene-modified bone marrow stromal cells (BMSCs) and Bio-Oss(®) for maxillary sinus floor augmentation (MSFA) implant placement in dogs. MATERIALS AND METHODS: BMSCs were derived from bone marrow of six beagles and cultured. The cells were transduced with a lentiviral vector overexpressing the DMP1 gene and enhanced green fluorescent protein (EGFP) gene (Lenti-DMP1/EGFP) in test group, and with a lentiviral vector encoding EGFP gene (Lenti-EGFP) in control group. Six dogs received sinus augmentations using the bilateral approach with a simultaneous implant placement at each site respectively. At the same concentration, 2×10(7) cells/ml, one sinus was grafted using a mixture of autologous DMP1/EGFP gene-modified BMSCs and Bio-Oss(®) (DMP1 group), and the contralateral sinus was grafted with autologous EGFP gene-modified bMSCs and Bio-Oss(®) (EGFP group). After a 3 month healing period, bone regeneration and osseointegration were evaluated using histologic and histomorphometric methods. RESULTS: The bone-implant contact (BIC) and the bone area fraction in the DMP1 group (BIC: 34.67%±8.23%, bone area fraction: 35.16%±3.32%) were significantly greater compared with the EGFP group (BIC: 26.06%±5.16%, bone area fraction: 20.74%±1.63%) (P<0.05). No significant difference between the residual bone substitute material volume (BSMV) in the DMP1 group (35.86±7.35) and the EGFP group (32.16±9.16) was found in our study (P>0.05). CONCLUSION: BMSCs modified with the DMP1 gene can be used as an adjunct to Bio-Oss(®) to enhance new bone formation and the osseointegration of dental implants in MSFA of dogs.
    [Abstract] [Full Text] [Related] [New Search]